Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
57 participants
OBSERVATIONAL
2022-09-22
2024-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Also,To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients. Moreover, to find the correlation between the movement disorder and the different types of MS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cerebellar RTMS in Patients with Multiple Sclerosis
NCT06265922
Postural Control and Psychosocial Measures Associations in Multiple Sclerosis
NCT06998147
Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions
NCT04639401
Pattern and Frequency of Non-epileptic Involuntary Movements
NCT04083586
Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis
NCT02896933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria:
i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).
iv. MRI Brain and spine of the included patient will be photographed.
Exclusion criteria:
1. Patients with multiple sclerosis mimics which can cause movement disorders e.g., systemic disease or overlap syndromes including systemic lupus, vasculitis, hepatic failure, renal failure, hyperthyroidism, electrolyte disturbances, Behcet's disease or CNS infection.
2. patients with primary movement disorders or related to other neurodegenerative diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple sclerosis patients with movement disorders.
A randomized cross-sectional study will be conducted on diagnosed multiple sclerosis patients who were diagnosed according to McDonald criteria of MS 2017 (Thompson et al. 2018).
We will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria:
i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).
iv. MRI Brain and spine of the included patient will be photographed.
Screen for movement disorder and correlates it with MRI findings.
* To determine the prevalence of movement disorders in MS patients.
* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.
* To find the correlation between the movement disorder and the different types of MS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Screen for movement disorder and correlates it with MRI findings.
* To determine the prevalence of movement disorders in MS patients.
* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.
* To find the correlation between the movement disorder and the different types of MS.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2-patients with primary movement disorders or related to other neurodegenerative diseases.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mostafa Mahmoud Hassan Meshref
Neurology physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mostafa Mahmoud Hassan Meshref
Cairo, Select A State Or Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Abboud H, Yu XX, Knusel K, Fernandez HH, Cohen JA. Movement disorders in early MS and related diseases: A prospective observational study. Neurol Clin Pract. 2019 Feb;9(1):24-31. doi: 10.1212/CPJ.0000000000000560.
Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004 Nov 15;70(10):1935-44.
Cameron MH, Nilsagard Y. Balance, gait, and falls in multiple sclerosis. Handb Clin Neurol. 2018;159:237-250. doi: 10.1016/B978-0-444-63916-5.00015-X.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Sep 15;15(9):545-58. doi: 10.1038/nri3871. Epub 2015 Aug 7.
Deuschl G. Movement disorders in multiple sclerosis and their treatment. Neurodegener Dis Manag. 2016 Dec;6(6s):31-35. doi: 10.2217/nmt-2016-0053.
Fragoso YD, Araujo MG, Branco NL. Kinesigenic paroxysmal hemidyskinesia as the initial presentation of multiple sclerosis. MedGenMed. 2006 Oct 4;8(4):3.
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J; MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017 Jul;23(8):1123-1136. doi: 10.1177/1352458517694432. Epub 2017 Feb 1.
Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013 May 15;328(1-2):1-8. doi: 10.1016/j.jns.2013.02.007. Epub 2013 Mar 19.
Nociti V, Bentivoglio AR, Frisullo G, Fasano A, Soleti F, Iorio R, Loria G, Patanella AK, Marti A, Tartaglione T, Tonali PA, Batocchi AP. Movement disorders in multiple sclerosis: Causal or coincidental association? Mult Scler. 2008 Nov;14(9):1284-7. doi: 10.1177/1352458508094883. Epub 2008 Sep 3.
Oakes PK, Srivatsal SR, Davis MY, Samii A. Movement disorders in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013 Nov;24(4):639-51. doi: 10.1016/j.pmr.2013.06.003. Epub 2013 Aug 27.
Suarez-Cedeno G, Mehanna R. Movement Disorders in Multiple Sclerosis and Other Demyelinating Diseases: A Retrospective Review From a Tertiary Academic Center. Neurologist. 2021 Sep 7;26(5):161-166. doi: 10.1097/NRL.0000000000000333.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar;18(3):269-285. doi: 10.1016/S1474-4422(18)30443-5. Epub 2019 Jan 21.
Waubant E, Alize P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001 Dec 26;57(12):2320-1. doi: 10.1212/wnl.57.12.2320. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Neuro-Med._0000044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.